How to cite: Crawford ED, and Petrylak DP. PARP Inhibitors and Genomic Testing in Metastatic Prostate Cancer: Lessons from TALAPRO-3. Grand Rounds in Urology. August 2026. Accessed Oct 2026. https://grandroundsinurology.com/parp-inhibitors-and-genomic-testing-in-metastatic-prostate-cancer-lessons-from-talapro-3/
Summary
In this UroDummies presentation, E. David Crawford, MD, Editor-in-Chief of Grand Rounds in Urology and Professor of Urology at the University of California, San Diego, San Diego, California, speaks with Daniel P. Petrylak, MD, Director of Genitourinary Oncology, Professor of Medicine and Urology, Yale University Cancer Center, New Haven, Connecticut, about poly (ADP-ribose) polymerase (PARP) inhibitors, synthetic lethality, genomic testing, and findings discussed from the TALAPRO-3 trial.
Dr. Petrylak explains that PARP inhibition exploits impaired DNA repair in prostate cancer cells. He describes synthetic lethality as using a PARP inhibitor to provide a second hit when BRCA or other DNA repair genes are altered, ultimately causing cancer cell death.
The discussion turns to TALAPRO-3 and the use of PARP inhibition earlier in metastatic hormone-sensitive prostate cancer. Dr. Petrylak states that genetic testing should be performed in castration-sensitive disease rather than reserved for castration-resistant disease. He also emphasizes that HRR alterations do not respond equally to PARP inhibition. BRCA2 appears to derive the greatest benefit, while BRCA1, ATM, ATR, and other DNA repair alterations may also be relevant.
Dr. Petrylak supports earlier treatment based on the broader concept that agents such as docetaxel, abiraterone, enzalutamide, apalutamide, and darolutamide can have greater effects when moved earlier in the disease course.
The discussion also addresses toxicity and testing strategy. Dr. Petrylak recommends both germline and somatic testing. Both Dr. Crawford and Dr. Petrylak emphasize that genetic testing for DNA repair alterations is an important component of evaluating newly diagnosed metastatic prostate cancer.
ABOUT THE AUTHOR
Researcher-physician E. David Crawford, MD, Jack A. Vickers Director of Prostate Research and Professor of Urology at the University of California, San Diego, San Diego, California, has devoted his career in medicine to educating the public about men's health issues and finding effective techniques and procedures to address prostate cancer, the most common malignancy affecting men in the United States.
Daniel P. Petrylak, MD, is a Professor of Medicine, specializing in Medical Oncology and Urology, and Chief of Genitourinary Oncology at Yale University Cancer Center in New Haven, Connecticut. Dr. Petrylak is an internationally renowned medical oncologist and is considered a pioneer in the research and development of new drugs and treatments to fight cancers of the prostate, bladder, and kidney.
